Tandem Diabetes Care (TNDM) Stock Price Target 2026

The average analyst price target for Tandem Diabetes Care is $27.90, 68.1% above the current price. Of 20 analysts, 11 rate it Buy and 9 Hold. Targets range from $12 to $60. The latest change came on Nov 6, 2026, when Barclays raised its price target on Tandem Diabetes Care from $18 to $20 and kept an Equal-Weight rating.

The Average Analyst Price Target for Tandem Diabetes Care is $27.90.

Price Target Range — 11 Quarters

Analyst Consensus — 20 Analysts

11Buy

9Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$27.90Upside to Avg. PT+68.1%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Tandem Diabetes Care Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 6, 2026	Barclays	Christopher Pasquale	PT Raise	Equal-Weight	$18→$20
Nov 6, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Overweight	$27→$25
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Equal-Weight	$18
Sep 30, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$24→$20
Sep 24, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$31→$28
Aug 21, 2026	William Blair	Steven Lichtman	Initiate	Outperform	—
Aug 7, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$17→$21
Aug 7, 2026	RBC Capital	Kendall Au	PT Cut	Outperform	$30→$26
Jul 28, 2026	UBS	Patrick Wood	Assumes	Neutral	$22→$18
Jul 15, 2026	Mizuho	Anthony Petrone	PT Cut	Neutral	$24→$20
Jun 23, 2026	Deutsche Bank	Kieran Ryan	Initiate	Buy→Hold	$16
Jun 1, 2026	Wells Fargo	Larry Biegelsen	Upgrade	Equal-Weight→Overweight	$21→$27
May 28, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$22→$17
May 18, 2026	B of A Securities	Travis Steed	PT Cut	Neutral	$35→$25
May 12, 2026	Benchmark	Bruce Jackson	Initiate	Hold	—
May 11, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$35→$31
May 11, 2026	Barclays	Matt Miksic	PT Cut	Overweight	$56→$55
Apr 20, 2026	TD Cowen	Mathew Blackman	PT Raise	Buy	$25→$28
Apr 9, 2026	Goldman Sachs	David Roman	PT Cut	Neutral	$28→$25
Mar 19, 2026	Truist Securities	Richard Newitter	Upgrade	Hold→Buy	$27→$35

Analyst Ratings News

PRO
Barclays Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $20

Barclays analyst Christopher Pasquale maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25

Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $27 to $25.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

Barclays analyst Christopher Pasquale initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight rating and announces Price Target of $18.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform rating.

Benzinga Newsdesk

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.

Vandana Singh

Tandem Diabetes Care Inc

Tandem Diabetes Care (TNDM) Stock Price Target 2026

The Average Analyst Price Target for Tandem Diabetes Care is $27.90.

Latest Upgrades and Downgrades for Tandem Diabetes Care Stock

Analyst Ratings News

PRO
Barclays Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $20

PRO
Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25

PRO
Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

PRO
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

People Also Watch

People Also Watch

Tandem Diabetes Care Inc

Tandem Diabetes Care (TNDM) Stock Price Target 2026

The Average Analyst Price Target for Tandem Diabetes Care is $27.90.

Latest Upgrades and Downgrades for Tandem Diabetes Care Stock

Analyst Ratings News

PROBarclays Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $20

PROWells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25

PROBarclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

PROCitigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

PROWilliam Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

People Also Watch

People Also Watch

PRO
Barclays Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $20

PRO
Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25

PRO
Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

PRO
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating